In focus · trending topic

rare genetic disease

2 stories · following the connections

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

By Nasdaq OMXNov 29, 2017, 12:00 PM UTC

ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

By Nasdaq OMXSep 19, 2017, 11:01 AM UTC